Objective To evaluate the surgical effects and methods of transurethral enucleation with 1470 nm diode laser for treatment of benign prostatic hyperplastia (BPH). Methods Clinical data of 56 cases with benign prostatic hyperplastia treated by transurethral enucleation with 1 470 nm diode laser from April 2015 to October 2015 were analyzed retrospectively. The surgical capsule was searched by way of endoscopic sheath (or adding vaporisation with 1 470 nm laser) pushing off the lateral lobe at 5 or 7 o'clock above the verumontanum. The adhesive prostatic tissue between gland and surgical capsule or between each lobe was ablated and stanched by 1 470 nm diode laser, then the middle lobe, left lateral lobe, and right lateral lobe were enucleated and pushed into bladder. The gland enucleated was performed by the morcellator system. Results The 56 cases underwent the procedure uneventfully. Enucleating gland time was 15～65 min with, morcellating tissue time 5～37 min, the weight of resected tissue was 29～152 g. There were no cases of transurethral resection syndrome, intestinal perforation, bladder perforation or transfusion. 5 cases had short term (≤4 w) urinary incontinence. There was significant difference of IPSS, QOL, Qmax before and after treatment (P < 0.01) in 3 months postoperatively. Conclusions 1 470 nm diode laser has the benefits of tissue ablation haemostasis, 1 470 nm DiLEP+tissue morcellating can not only resect the hyperplastic gland as complete as possible, stop bleeding much more thorough, but also save the operation time.